Dow Inc. is trying to walk away from a $20 billion chemicals plant in Saudi Arabia, and the numbers explain why. The company's stake in Sadara Chemical, a sprawling joint venture with Saudi Aramco, has flipped from an asset into a liability so severe that Dow's own books show a negative investment balance of $793 million.

That is not a paper loss. It represents real financial exposure: obligations tied to the venture's debt, a credit facility that Sadara has already drawn on, and the prospect of Dow having to pump more cash in just to keep things stable. CEO Jim Fitterling said earlier this year that the company's goal for 2026 was simply to avoid putting additional money into Sadara at all. When that becomes the ambition, the underlying investment has clearly stopped working.

How a flagship project became a financial burden

Sadara was supposed to be a signature achievement. Built in Jubail, on Saudi Arabia's Gulf coast, the complex runs more than 3 million metric tons of annual chemicals and plastics capacity. When the joint venture came together, it represented the kind of scale that chemicals companies chase: access to cheap feedstocks, a strategic partnership with one of the world's largest oil producers, and a foothold in a region investing heavily in industrial expansion.

What it ran into instead was a global chemicals industry that has been in prolonged trouble. Demand is weak. Supply is high, partly because China built enormous capacity over the past decade that is now washing through global markets. Margins across the industry have been compressed for long enough that major players, including Dow, are rethinking which assets they actually want to own.

Sadara's problems did not stop there. Earlier this year, operations at Jubail were disrupted by the Middle East conflict, adding transportation and supply-chain pressure on top of an already difficult market. The venture has high fixed costs and financing obligations that are hard to manage when selling prices are low and volume growth is slow.

What a sale would and would not solve

If Dow finds a buyer, whether Saudi Aramco acquires the full stake or a financial investor steps in, the immediate benefit is straightforward. Dow removes a persistent drag on its cash flow and stops being on the hook for future funding requirements at Sadara. For a company that has set free-cash-flow breakeven as a near-term target and is actively cutting costs across the business, that matters.

The harder question is what selling a $20 billion stake in a money-losing venture actually fetches. No final decision has been made, and the terms of any eventual deal are unknown. A distressed seller rarely gets full value, and Dow's negative investment balance signals that the market already understands what the venture is worth in its current state.

For Dow's shareholders, the calculus is not primarily about the sale price. It is about whether management can redirect whatever capital and attention is freed up toward parts of the portfolio that generate returns. The company has framed this as a broader restructuring, reviewing assets and concentrating resources on businesses with stronger economics.

The Sadara situation is also a useful lens on how the chemicals industry more broadly is sorting itself out. Years of overbuilding, particularly in Asia, have left the sector with too much supply chasing too little demand. Companies that made large, long-cycle capital commitments when the outlook looked different are now having to decide whether to hold through the downturn or cut their losses. Dow is not alone in facing that choice. It is simply one of the more visible examples of how those decisions look when the numbers turn negative.

For now, Dow is exploring options. The outcome will depend on whether Aramco or another buyer sees value in a complex that, even burdened by debt and a difficult market, still represents significant industrial scale.